Chimerix - CMRX Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price targets for Chimerix's shares. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 282.9% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.

Chimerix's stock was trading at $6.43 at the beginning of the year. Since then, CMRX shares have decreased by 65.5% and is now trading at $2.22.
View the best growth stocks for 2022 here.

Chimerix saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 3,170,000 shares, a decline of 8.9% from the October 31st total of 3,480,000 shares. Based on an average trading volume of 1,750,000 shares, the short-interest ratio is currently 1.8 days. Approximately 4.3% of the company's shares are short sold.
View Chimerix's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our CMRX earnings forecast.

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, meeting analysts' consensus estimates of ($0.21). The biopharmaceutical company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.39 million. Chimerix had a trailing twelve-month return on equity of 147.04% and a net margin of 464.75%. During the same quarter in the prior year, the business earned ($0.18) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (7.52%), BlackRock Inc. (6.55%), Vanguard Group Inc. (5.10%), State Street Corp (3.31%), Armistice Capital LLC (3.13%) and Monaco Asset Management SAM (2.41%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends.

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CMRX stock can currently be purchased for approximately $2.22.

Chimerix (NASDAQ:CMRX) has a market capitalization of $195.46 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.